Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Belluscura PLC ( (GB:BELL) ) has provided an announcement.
Belluscura PLC announced the termination of a $1.5 million Loan Note agreement with Omaha Value, Inc due to non-receipt of funds, resulting in the cancellation of related warrants. The company is exploring strategic alternatives to maximize value for stakeholders, including a potential asset sale to a US medical device company. This potential sale, which involves key assets and intellectual property, is under a 15-day exclusivity period for due diligence. The company’s shares remain suspended as it continues funding discussions and delays the finalization of its 2024 Annual Report.
More about Belluscura PLC
Belluscura PLC is a UK-based medical device company specializing in the development of oxygen enrichment technology, catering to various industries and therapeutic applications.
Average Trading Volume: 5,462,662
Technical Sentiment Signal: Sell
Current Market Cap: £3.01M
For a thorough assessment of BELL stock, go to TipRanks’ Stock Analysis page.